Enzymatica: Initial take of Q4 2022 results - Redeye

Redeye provides an initial take on Enzymatica’s Q4 2022 report. The year has not lived up to our expectations, with total sales of SEK48.9m (SEK57.2m), which can be compared to our sales estimate of SEK56.8m. The company is still clearly affected by the Covid-19 pandemic and is the main reason for the year’s result. We will provide a more in-depth update shortly, where we expect to change our future estimates downwards.

Länk till analysen i sin helhet: https://www.redeye.se/research/879797/enzymatica-initial-take-of-q4-2022-results?utm_source=finwire&utm_medium=RSS